May-Britt Tessem's research activity make use of integrated multi-omics technology (metabolomics, proteomics, transcriptomics, genomics) to study tissue samples and biofluids (urine, blood) from large-scale biobanks from prostate cancer patients. Important methodologies are MR spectroscopy (HR MAS MRS), MS MALDI-imaging, RNA sequencing and immunohistochemistry. The main research aim is to discover and validate biomarkers and molecular signatures for separating aggressive from indolent prostate cancer.